Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company, announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company will present and hold one-on-one meetings with investors. A recorded presentation will be available on-demand starting September 13 on Anebulo’s website. Anebulo focuses on developing solutions for acute cannabinoid intoxication and substance addiction, with its lead candidate, ANEB-001, showing promising results in clinical trials.

AUSTIN, Texas--(BUSINESS WIRE)-- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that management will be participating in the H.C. Wainwright 23^rd Annual Global investment Conference being held virtually on September 13-15, 2021. Management will deliver a company presentation and will be available for one-on-one meetings with investors. The recorded presentation will be available on demand beginning Monday, September 13^th on the Investors section of Anebulo’s website.

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit www.anebulo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005053/en/

Anebulo Pharmaceuticals, Inc.

Rex Merchant

Chief Financial Officer

(512) 598-0931

IR@anebulo.com

LHA Investor Relations

Yvonne Briggs

(310) 691-7100

ybriggs@lhai.com

Source: Anebulo Pharmaceuticals, Inc.

FAQ

When is Anebulo Pharmaceuticals participating in the H.C. Wainwright Global Investment Conference?

Anebulo Pharmaceuticals will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

What is the focus of Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals focuses on developing novel solutions for acute cannabinoid intoxication and substance addiction.

What is Anebulo's lead product candidate?

Anebulo's lead product candidate is ANEB-001, which aims to reverse the negative effects of acute cannabinoid intoxication.

When will the recorded presentation by Anebulo be available?

The recorded presentation by Anebulo will be available on-demand starting September 13, 2021.

What key outcomes have been observed in Anebulo's clinical trials for ANEB-001?

Clinical trials for ANEB-001 have shown that it is rapidly absorbed, well tolerated, and leads to weight loss.